Cross Talk between α7 and α3β4 Nicotinic Receptors Prevents Their Desensitization in Human Chromaffin Cells.


Journal

The Journal of neuroscience : the official journal of the Society for Neuroscience
ISSN: 1529-2401
Titre abrégé: J Neurosci
Pays: United States
ID NLM: 8102140

Informations de publication

Date de publication:
16 02 2022
Historique:
received: 24 05 2021
revised: 24 11 2021
accepted: 05 12 2021
pubmed: 31 12 2021
medline: 26 2 2022
entrez: 30 12 2021
Statut: ppublish

Résumé

The physical interaction and functional cross talk among the different subtypes of neuronal nicotinic acetylcholine receptors (nAChRs) expressed in the various tissues is unknown. Here, we have investigated this issue between the only two nAChRs subtypes expressed, the α7 and α3β4 subtypes, in a human native neuroendocrine cell (the chromaffin cell) using electrophysiological patch-clamp, fluorescence, and Förster resonance energy transfer (FRET) techniques. Our data show that α7 and α3β4 receptor subtypes require their mutual and maximal efficacy of activation to increase their expression, to avoid their desensitization, and therefore, to increase their activity. In this way, after repetitive stimulation with acetylcholine (ACh), α7 and α3β4 receptor subtypes do not desensitize, but they do with choline. The nicotinic current increase associated with the α3β4 subtype is dependent on Ca

Identifiants

pubmed: 34965978
pii: JNEUROSCI.1115-21.2021
doi: 10.1523/JNEUROSCI.1115-21.2021
pmc: PMC8883849
doi:

Substances chimiques

Receptors, Nicotinic 0
alpha7 Nicotinic Acetylcholine Receptor 0
nicotinic receptor alpha3beta4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1173-1183

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM103801
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM136430
Pays : United States

Informations de copyright

Copyright © 2022 the authors.

Références

Biochemistry. 2007 Jun 5;46(22):6628-38
pubmed: 17497892
Pflugers Arch. 1988 Feb;411(2):137-46
pubmed: 3357753
J Neurosci. 2005 Apr 6;25(14):3712-23
pubmed: 15814802
Anal Bioanal Chem. 2013 Feb;405(6):2009-17
pubmed: 23232958
J Neurochem. 2017 Jan;140(1):37-52
pubmed: 27805736
J Neurochem. 1996 Sep;67(3):1100-12
pubmed: 8752117
J Biol Chem. 2013 Aug 30;288(35):25428-25439
pubmed: 23846688
Eur J Pharmacol. 2001 Nov 2;430(2-3):175-83
pubmed: 11711029
Brain Res Brain Res Protoc. 2001 Feb;6(3):134-40
pubmed: 11223412
J Neurophysiol. 1995 Sep;74(3):1212-21
pubmed: 7500145
Neuroscience. 2003;118(4):1175-82
pubmed: 12732260
Genes Brain Behav. 2016 Jan;15(1):89-107
pubmed: 26351737
FASEB J. 2012 Jan;26(1):346-54
pubmed: 21917987
Nutrients. 2019 Oct 22;11(10):
pubmed: 31652561
J Neurochem. 2011 Jan;116(1):105-21
pubmed: 21054386
Neurobiol Aging. 2015 Jan;36(1):188-200
pubmed: 25219467
J Neurochem. 2012 Nov;123(4):504-14
pubmed: 22913551
Eur J Neurosci. 2005 Oct;22(8):1942-50
pubmed: 16262633
Nutrition. 2000 Jul-Aug;16(7-8):669-71
pubmed: 10906592
Neuropharmacology. 2021 Sep 1;195:108632
pubmed: 34097947
Nat Methods. 2018 Sep;15(9):669-676
pubmed: 30171252
Mol Pharmacol. 2015 Nov;88(5):881-93
pubmed: 26330550
J Neurochem. 2007 Dec;103(6):2281-90
pubmed: 17883397
J Neurochem. 1993 Sep;61(3):921-7
pubmed: 8395566
J Neurosci. 2005 Oct 26;25(43):9836-49
pubmed: 16251431
Neurosci Lett. 1996 Aug 9;213(3):201-4
pubmed: 8873149
J Med Chem. 2013 Dec 12;56(23):9655-63
pubmed: 24200193
Am J Pathol. 2005 Jun;166(6):1761-71
pubmed: 15920161
Br J Pharmacol. 2012 Feb;165(4):908-21
pubmed: 21790533

Auteurs

Amanda Jiménez-Pompa (A)

Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid 28029, Spain.
Instituto-Fundación Teófilo Hernando, Madrid 28029, Spain.

Sara Sanz-Lázaro (S)

Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid 28029, Spain.

Romidan Ewere Omodolor (RE)

Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid 28029, Spain.

José Medina-Polo (J)

Servicio de Urología, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid 28041, Spain.

Carmen González-Enguita (C)

Servicio de Urología y Unidad de Trasplante Renal, Fundación Jiménez Díaz, Madrid 28040, Spain.

Jesús Blázquez (J)

Servicio de Urología, Hospital Clínico San Carlos, Madrid 28040, Spain.

J Michael McIntosh (JM)

Departments of Biology and Psychiatry, University of Utah, Salt Lake City, UT 84108.
George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84108.

Almudena Albillos (A)

Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid 28029, Spain almudena.albillos@uam.es.
Instituto Ramón y Cajal de Investigación Biosanitaria (IRYCIS), Madrid 28034, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH